loading
Astria Therapeutics Inc stock is traded at $6.56, with a volume of 100.28K. It is down -1.80% in the last 24 hours and up +13.89% over the past month. Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$6.68
Open:
$6.68
24h Volume:
100.28K
Relative Volume:
0.22
Market Cap:
$370.21M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-2.7107
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
+5.13%
1M Performance:
+13.89%
6M Performance:
-11.47%
1Y Performance:
-42.81%
1-Day Range:
Value
$6.48
$6.73
1-Week Range:
Value
$5.9404
$6.73
52-Week Range:
Value
$3.555
$12.92

Astria Therapeutics Inc Stock (ATXS) Company Profile

Name
Name
Astria Therapeutics Inc
Name
Phone
617-349-1971
Name
Address
22 BOSTON WHARF ROAD, BOSTON
Name
Employee
78
Name
Twitter
Name
Next Earnings Date
2025-03-11
Name
Latest SEC Filings
Name
ATXS's Discussions on Twitter

Compare ATXS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ATXS
Astria Therapeutics Inc
6.56 362.31M 0 -72.89M -68.47M -2.42
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-29-25 Initiated Cantor Fitzgerald Overweight
Jan-31-25 Initiated JMP Securities Mkt Outperform
Jul-29-24 Initiated TD Cowen Buy
Mar-28-23 Initiated Evercore ISI Outperform

Astria Therapeutics Inc Stock (ATXS) Latest News

pulisher
03:38 AM

What analysts say about Astria Therapeutics Inc. stockFree Stock Market Forecast Reports - Autocar Professional

03:38 AM
pulisher
Jul 23, 2025

What drives Astria Therapeutics Inc. stock priceConsistent double returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Astria Therapeutics Inc. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Astria Therapeutics Inc. a good long term investmentFree Market Dynamics Reports - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 19, 2025

Published on: 2025-07-19 19:06:02 - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Will Astria Therapeutics Inc. stock split in the near futureFree Stock Market Trend Analysis - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

why astria therapeutics inc. stock attracts strong analyst attentionPortfolio Boosting Stock Alerts - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

How Astria Therapeutics Inc. stock performs during market volatilityTechnical Breakout List - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Why Astria Therapeutics Inc. stock attracts strong analyst attentionFree Professional Portfolio Management - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Astria Therapeutics Inc. stock price move sharplyFree Access to Stock Community - beatles.ru

Jul 15, 2025
pulisher
Jul 15, 2025

Astria: Betting On Navenibart In The Crowded HAE Arena - Seeking Alpha

Jul 15, 2025
pulisher
Jul 09, 2025

Astria Therapeutics (ATXS) Soars 5.62% on Positive Trial Results - AInvest

Jul 09, 2025
pulisher
Jul 08, 2025

Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com

Jul 08, 2025
pulisher
Jul 07, 2025

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - BioSpace

Jul 07, 2025
pulisher
Jul 07, 2025

Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Analysts - Defense World

Jul 07, 2025
pulisher
Jul 03, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 2, 2025 - BioSpace

Jul 03, 2025
pulisher
Jun 29, 2025

Trading (ATXS) With Integrated Risk Controls - news.stocktradersdaily.com

Jun 29, 2025
pulisher
Jun 18, 2025

(ATXS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 18, 2025

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit - BioSpace

Jun 18, 2025
pulisher
Jun 18, 2025

Astria Therapeutics to Participate in Upcoming Oppenheimer Innov - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Astria CEO Discusses Breakthrough Dermatology Treatments at Major Oppenheimer Summit - Stock Titan

Jun 18, 2025
pulisher
Jun 16, 2025

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress - BioSpace

Jun 16, 2025
pulisher
Jun 15, 2025

Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $30.00 - Defense World

Jun 15, 2025
pulisher
Jun 15, 2025

HC Wainwright Reaffirms “Buy” Rating for Astria Therapeutics (NASDAQ:ATXS) - Defense World

Jun 15, 2025

Astria Therapeutics Inc Stock (ATXS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Cap:     |  Volume (24h):